The United Kingdom and the United States have finalized a significant commercial pact that will keep no import taxes on British pharmaceutical exports going into the US market.
Agreement Details of the Pact
In exchange for the tariff guarantee, the UK has committed to raise funding on drugs through the public health system. This move guarantees that import taxes on these vital goods will be held at nothing for a timeframe of 36 months.
This agreement comes after previous warnings to significantly raise import taxes on branded drug imports, with increases floated as high as 100%.
"This deal between the United Kingdom strengthens the international landscape for new treatments and establishes much-needed balance to U.S.–U.K. pharmaceutical trade," a release said.
Economic Significance
Pharmaceuticals represent one of the the United Kingdom's most significant exports to the United States, which is clearly the largest buyer for major UK drugmakers.
Trade data indicate that in the one-year period to the end of September, the UK shipped pharmaceutical products valued at billions to the US. This amount represented nearly one-fifth of all goods exports in that period.
"This deal protects employment, boosts capital expenditure and sets the stage for the UK to become a worldwide center for medical research," a government official commented.
Key UK Commitments
The deal involves several specific commitments from the UK:
- Price Threshold Increase: The UK will raise the cost ceiling at which it deems new treatments to be too expensive by twenty-five percent.
- Increased NHS Spending: There is a goal to raise total public funding on drugs from 0.3% of Gross Domestic Product to 0.6 percent over the coming ten years.
- Refund Ceiling: The amount pharmaceutical firms must refund to the NHS to stay within budget will be limited at fifteen percent. In the past, rebates exceeded twenty percent.
Broader Context
The deal follows a long-running row between the drug companies and the British authorities over spending levels and NHS adoption.
This friction were exacerbated by claims that US patients were charged a premium for the same drugs than people in the UK and Europe.
In recent months, several significant pharmaceutical investments in the UK have been paused or scrapped, while major investments have been announced toward projects in the United States.
The Science Minister acknowledged that the NHS had to spend more on drugs, noting that its spending on drugs had decreased as a percentage of its overall budget over the last ten years.
